4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM)
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Placebo (middle dose)Drug: BI 10773Drug: PlaceboDrug: Placebo (high dose)Drug: Placebo (low dose)
- First Posted Date
- 2009-04-21
- Last Posted Date
- 2014-11-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 100
- Registration Number
- NCT00885118
- Locations
- 🇯🇵
1245.15.003 Boehringer Ingelheim Investigational Site, Hachioji, Tokyo, Japan
🇯🇵1245.15.002 Boehringer Ingelheim Investigational Site, Koganei, Tokyo, Japan
🇯🇵1245.15.005 Boehringer Ingelheim Investigational Site, Suita, Osaka, Japan
Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2009-04-15
- Last Posted Date
- 2014-06-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 660
- Registration Number
- NCT00881530
- Locations
- 🇺🇸
1245.24.101006 Boehringer Ingelheim Investigational Site, Wadsworth, Ohio, United States
🇺🇸1245.24.101024 Boehringer Ingelheim Investigational Site, St. Cloud, Florida, United States
🇺🇸1245.24.101015 Boehringer Ingelheim Investigational Site, Dallas, Texas, United States
Investigating the Effect of Telmisartan (Micardis®) on the Average 24h Blood Pressure of Therapy-naive and Therapy-experienced Patients
- First Posted Date
- 2009-04-10
- Last Posted Date
- 2014-03-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 670
- Registration Number
- NCT00879411
Telmisartan Fixed Dose Combination vs Amlodipine in Hypertensive Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2009-04-08
- Last Posted Date
- 2014-03-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 706
- Registration Number
- NCT00877929
- Locations
- 🇺🇸
1235.21.907 Boehringer Ingelheim Investigational Site, Tustin, California, United States
🇺🇸1235.21.913 Boehringer Ingelheim Investigational Site, Fort Lauderdale, Florida, United States
🇺🇸1235.21.910 Boehringer Ingelheim Investigational Site, Hollywood, Florida, United States
Non-Interventional Observational Study With Viramune Plus Antiretroviral in HIV Infected Patients
- Conditions
- HIV Infections
- First Posted Date
- 2009-04-07
- Last Posted Date
- 2015-01-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 605
- Registration Number
- NCT00876733
- Locations
- 🇩🇪
Boehringer Ingelheim Investigational Site 15, Berlin, Germany
🇩🇪Boehringer Ingelheim Investigational Site 12, Berlin, Germany
🇩🇪Boehringer Ingelheim Investigational Site 14, Aachen, Germany
BIBF 1120 + Docetaxel (Japan) in Patients With Advanced Non-small-cell Lung Cancer, Phase I
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Drug: BIBF 1120 M + docetaxel MDrug: BIBF 1120 M + docetaxel HDrug: BIBF 1120 H + docetaxel HDrug: BIBF 1120 L + docetaxel MDrug: BIBF 1120 H + docetaxel M
- First Posted Date
- 2009-04-06
- Last Posted Date
- 2016-11-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 43
- Registration Number
- NCT00876460
- Locations
- 🇯🇵
1199.29.002 Boehringer Ingelheim Investigational Site, Fukuoka, Fukuoka, Japan
🇯🇵1199.29.001 Boehringer Ingelheim Investigational Site, Osaka-Sayamashi, Osaka, Japan
Afatinib (BIBW 2992) QTcF Trial in Patients With Relapsed or Refractory Solid Tumours
- First Posted Date
- 2009-04-03
- Last Posted Date
- 2013-12-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 60
- Registration Number
- NCT00875433
- Locations
- 🇬🇧
1200.24.4401 Boehringer Ingelheim Investigational Site, Sutton, United Kingdom
🇬🇧1200.24.4402 Boehringer Ingelheim Investigational Site, London, United Kingdom
🇬🇧1200.24.4403 Boehringer Ingelheim Investigational Site, Guildford, United Kingdom
Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2009-03-12
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 858
- Registration Number
- NCT00860262
- Locations
- 🇧🇬
1235.20.008 Boehringer Ingelheim Investigational Site, Sofia, Bulgaria
🇭🇺1235.20.152 Boehringer Ingelheim Investigational Site, Budapest, Hungary
🇷🇴1235.20.254 Boehringer Ingelheim Investigational Site, Iasi, Romania
Assess the Efficacy and Tolerability of Antistax Film-coated Tablets in Patients With Chronic Venous Insufficiency
- Conditions
- Venous Insufficiency
- Interventions
- Drug: Red vine leaf extract (AS 195)Drug: Placebo
- First Posted Date
- 2009-03-04
- Last Posted Date
- 2014-05-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 250
- Registration Number
- NCT00855179
- Locations
- 🇩🇪
1138.11.49004 Boehringer Ingelheim Investigational Site, Berlin, Germany
🇩🇪1138.11.49023 Boehringer Ingelheim Investigational Site, Breisach, Germany
🇩🇪1138.11.49010 Boehringer Ingelheim Investigational Site, Lübeck, Germany
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of AbGn-168 in Psoriasis
- Conditions
- Psoriasis
- Interventions
- Drug: AbGn168 intravenous infusionDrug: AbGn168 subcutaneous injection
- First Posted Date
- 2009-02-20
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 40
- Registration Number
- NCT00848055
- Locations
- 🇺🇸
1240.1.05 Boehringer Ingelheim Investigational Site, Boise, Idaho, United States
🇺🇸1240.1.03 Boehringer Ingelheim Investigational Site, Dallas, Texas, United States
🇺🇸1240.1.04 Boehringer Ingelheim Investigational Site, Baltimore, Maryland, United States